PRF Technologies FY26 H1 net loss widens to $2.8 million
PRFX•PRF Technologies widens first-half loss
PRF Technologies posted a net loss attributable to shareholders of $2.8 million for the six months ended June 30, 2026, widening from $2.3 million.
R&D rises on Solar and LayerBio activity
R&D expenses rose to $0.8 million from $0.3 million, due to expanded Solar activity and increased LayerBio clinical development.
G&A costs fell 39% to $1.2 million on lower consulting, legal and share-based compensation expenses.
Cash balance increases and OcuRing-K advances
Cash, cash equivalents, short-term deposits and restricted cash climbed to $11.6 million at June 30, up from $4.2 million at year-end 2025.
The FDA cleared the IND for OcuRing-K ahead of a U.S. Phase II cataract surgery trial, with enrollment expected in the second half of 2026.
